Építés alatt – nem éles oldal
Belépés
Még nem keres résztvevőt itt: Egyesült Államok1/2. fázis

Disulfiram for Preventing Treatment Complications in Patients Undergoing CAR T-cell Therapy for Relapsed or Refractory Diffuse Large B-cell Lymphoma

A legfontosabb adatok

Ki végzi
University of Michigan Rogel Cancer Center
Hol
Ann Arbor (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
1/2. fázis
Résztvevők
12 fő, tervezett
Kezdés
2026. nov.
Várható befejezés
2028. máj.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Axicabtagene Ciloleucel
  • Biospecimen Collection
  • Computed Tomography
  • Cyclophosphamide
  • Disulfiram
  • Fludarabine
  • Positron Emission Tomography
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 22 feltétel megnézéseKevesebb

Ki vehet részt

  • Histologic diagnosis of relapsed/refractory large B-cell lymphoma
  • >= 18 years of age at the time of signing informed consent (ICF)
  • Understands and voluntarily signs the ICF prior to conduct of any study-related assessments or procedures
  • Willing to adhere to the study visit schedule and other protocol requirements
  • Willing/able to abstain from any drug/substance at risk for reaction with disulfiram for the duration of treatment
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 2
  • Eligible for therapy with axicabtagene ciloleucel per institutional criteria
  • Confirmation of a manufactured CAR T-cell product within clinical specifications for axicabtagene ciloleucel
  • Females and males of childbearing potential must be willing to use effective methods of contraception from the time of informed consent until 12 months (female) or 4 months (males with female partners of reproductive potential) after the cyclophosphamide infusion
  • Willingness to consent / co-enroll on the University of Michigan cellular therapy long-term follow-up study - HUM00043287 (UMCC2001-0234)

Ki nem vehet részt

  • Active concurrent autoimmune disease requiring systemic immunosuppression
  • Active clinically relevant central nervous system disease including but not limited to:; Seizures/Epilepsy; Stroke or unstable neurologic deficits within the past 12 months prior to enrollment; Cerebral edema; Aphasia; Severe brain injury; Cerebellar disease; Documented history of dementia as confirmed by neuropsychiatric testing; Parkinson's disease; Psychosis
  • Current or previous treatment with any other agents explicitly for prophylaxis of CRS or ICANS, including corticosteroids and investigational agents during the study enrollment period. Corticosteroids given for disease treatment should have a washout of at least 5 half-lives prior to cell infusion. Use of prophylactic antiseizure medications is not contraindicated
  • Concurrent use of prohibited medications or substances at risk of precipitating a disulfiram reaction
  • Serious or uncontrolled infection defined as not having cleared infection despite being on appropriate antimicrobial therapy for 5 days would be excluded. Also any infection which, in the opinion of the investigator, places the patient at an unacceptable risk for treatment-related complications, could impede the ability to safely administer therapy, or could interfere with evaluation of study intervention
  • Active hepatitis B or C (latent hepatitis B will not be excluded), or HIV. Entecavir prophylaxis can be used for latent hepatitis B. A patient's viral load must be undetectable per quantitative polymerase chain reaction (PCR) and/or nucleic acid testing at screening
  • Any other significant medical condition (including neurological or psychiatric) which, in the opinion of the investigator, places the participant at an unacceptable risk for treatment-related complications, could interfere with the successful or safe delivery of therapy, or could interfere with evaluation of study intervention or interpretation of participant safety or study results. Including but not limited to:; Diabetes with associated autonomic dysfunction; Uncontrolled Hypothyroidism; Chronic or acute nephritis; Hepatic cirrhosis/insufficiency
  • Hypersensitivity to disulfiram or to other thiuram derivatives used in pesticides and rubber vulcanization
  • Total bilirubin of >= 1.5 x upper limit of normal (ULN) unless attributed to Gilbert's syndrome or underlying primary malignancy. Patients with Gilbert syndrome or underlying primary malignancy involving the liver with total bilirubin >= 2.5 x ULN (or absolute total bilirubin >= 3 mg/dL) should be excluded. Aspartate aminotransferase (AST): >= 2.5 x ULN, alanine aminotransferase (ALT): >= 2.5 x ULN
  • History of, or a concurrent, clinically significant illness, medical condition or laboratory abnormality that, in the investigator's opinion, could affect the conduct of the study
  • Active primary or secondary central nervous system (CNS) lymphoma
  • Pregnant or nursing females

Helyszínek itt: Egyesült Államok

  • University of Michigan Rogel Cancer CenterAnn Arbor, Egyesült ÁllamokContact: Tracey ChurayToborzás még nem indult

A vizsgálatról

Mit akar kideríteni a vizsgálat

This phase I/II trial tests the safety, best dose, and effectiveness of disulfiram for preventing treatment complications in patients with large B-cell lymphoma that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and who are undergoing chimeric antigen receptor (CAR) T-cell therapy. Two major complications of CAR T-cell therapy include cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). CRS results from inflammation in the body when the immune system responds too aggressively to the modified T cells working to attack cancer cells. ICANS is inflammation of the brain or nerves. CRS is most often a prelude to ICANS, and both of these toxicities currently require immunosuppression for treatment, which can inhibit CAR T-cell response. Disulfiram has been found to impact several biologic pathways that cause CRS. Disulfiram may be safe and effective for reducing the incidence and severity of reactions to CAR T-cell therapy without inhibiting CAR T-cell response.

A vizsgálat csoportja

  • Supportive care (disulfiram)A vizsgált kezelés

    Patients receive disulfiram PO QD on days -5 to +21. Patients receive cyclophosphamide IV and fludarabine IV on days -5 to -3 and then receive axi-cel IV on day 0. Patients also undergo CT or PET/CT at screening and follow-up and undergo collection of blood samples throughout the trial.

    Kezelés: Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Disulfiram, Fludarabine és Positron Emission Tomography

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Single Center, Phase I/II Study of Disulfiram for the Prevention of Immunotoxicity in Patients Undergoing CAR T-Cell Therapy
A regiszteradat frissítve
2026. november 12.